ITGR — Integer Holdings Corporation stock price, charts and financials

QT75Integer Holdings Corporation

Integer Holdings Corporation (NYSE: ITGR) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
125.07
-0.20-0.16%
ITGRQT75Integer Holdings Corporation·NYSE
125.07-0.16%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E33.95EPS (ttm)3.69Insider Own2.60%Shs Outstand33.95MPerf Week3.35%
Market Cap4.25BForward P/E18.23EPS next Y6.87Insider Trans-0.09%Shs Float33.52MPerf Month36.24%
Enterprise Value5.60BPEG0.65EPS next Q-Inst Own-Short Float12.99%Perf Quarter42.48%
Income128.03MP/S2.31EPS this Y52.65%Inst Trans-Short Ratio8.10Perf Half Y46.98%
Sales1.84BP/B2.48EPS next Y12.28%ROA3.75%Short Interest4.35MPerf YTD59.72%
Book/sh-P/C20.74EPS next 5Y11.83%ROE7.43%52W High125.94 -0.69%Perf Year18.90%
Cash/sh-P/FCF37.99EPS past 3/5Y13.82% 4.40%ROIC5.11%52W Low61.90 102.05%Perf 3Y35.62%
Dividend Est.-EV/EBITDA17.88Sales past 3/5Y11.52% 11.46%Gross Margin23.73%Volatility0.66% 3.28%Perf 5Y27.97%
Dividend TTM-EV/Sales3.04EPS Y/Y TTM17.94%Oper. Margin9.47%ATR (14)3.36Perf 10Y293.19%
Dividend Ex-Date-Quick Ratio2.41Sales Y/Y TTM7.80%Profit Margin6.97%RSI (14)83.27Recom2.44
Dividend Gr. 3/5Y-Current Ratio3.73EPS Q/Q-8.40%SMA2018.58%Beta0.61Target Price114.80
Payout0.00%Debt/Eq0.79Sales Q/Q0.92%SMA5028.72%Rel Volume1.30Prev Close125.27
Employees11,000LT Debt/Eq0.79EarningsOct 22SMA20046.46%Avg Volume813.14KPrice125.07
IPO DateSep 29, 2000Option/ShortYes / YesEPS/Sales Surpr.1.25% 3.07%Net Debt/EBITDA4.29Volume1,055,797Change-0.16%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26DowngradeFreedom Capital MarketsBuyHold
Aug-04-26DowngradeOppenheimerOutperformPerform
Aug-04-26DowngradeTruist SecuritiesBuyHold$127
Aug-03-26ReiteratedPiper SandlerOverweight$82$127
Aug-03-26DowngradeKeybancOverweightSector Weight
Jul-21-26ReiteratedKeyBancOverweight$133$104
Jul-16-26ReiteratedTruist SecuritiesBuy$95$110
May-13-26UpgradeOppenheimerPerformOutperform$115
Feb-23-26ReiteratedRaymond JamesOutperform$95$101
Feb-20-26UpgradeBenchmarkHoldBuy
Latest News
Aug-07-26
Aug-05-26
Aug-03-26
Jul-31-26
Company

Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,8421,8461,717
Cost of Goods Sold Incl. D&A1,4041,4211,255
Gross Profit437426461
Selling, General and Administrative Excl. Other195163184
Research and Development484653
Other Operating Expense19816
Operating Income175209208
Interest Expense384256
Unusual Expense
Non-Operating Income (Expense)1-42-4
Net Income Before Taxes136125148
Income Taxes82327
Consolidated Net Income130103120
Net Income From Continuing Operations130103121
Net Income130103120
EPS (Recurring)3.692.963.60
EPS (Basic, Before Extraordinaries)3.692.963.60
EPS (Diluted)3.662.893.40
EBITDA313294333
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio34.1727.1438.98
Price To Sales Ratio2.311.492.62
Gross Margin23.7223.0826.85
Operating Margin9.5011.3212.11
Net Margin7.065.586.99
Shares Outstanding343534
Market Capitalization4,2522,7454,506
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$135.48$115.09$94.69$74.30$53.91 Close Price0.00K74.30K148.59K222.89K297.19KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thor Kirk KChief Human Resources OfficerJun 30 '26Option Exercise0.006,120041,102Jul 01
Stephens JimPresident, CRM & NeuroMay 15 '26Option Exercise0.001,96306,331May 19
Smith DironEVP, Chief Financial OfficerMay 08 '26Option Exercise0.002,063013,422May 12
Harris John AEVP, Global Ops and ManufacturMar 31 '26Option Exercise0.003,837010,499Apr 02
Blackwood Lindsay K.SVP, Gen Counsel & SecretaryMar 24 '26Option Exercise0.003,48303,483Mar 25
Carr TerenceEVP, Qlty & Regulatory AffairsMar 24 '26Option Exercise0.001,35001,350Mar 25
Thomas Tommy PVP, Corporate ControllerMar 13 '26Sale85.0082570,1254,381Mar 17
Khales PaymanPresident & CEOFeb 24 '26Option Exercise0.0043,060078,799Feb 24
Thomas Tommy PVP, Corporate ControllerJan 20 '26Option Exercise0.0033704,391Jan 21
Smith DironEVP, Chief Financial OfficerJan 20 '26Option Exercise0.00292011,058Jan 21
Thor Kirk KChief Human Resources OfficerJan 20 '26Option Exercise0.00816028,750Jan 21
Senn AndrewSVP, Strategy and Business DevJan 20 '26Option Exercise0.002,224012,625Jan 21
Khales PaymanPresident & CEOJan 20 '26Option Exercise0.001,348026,434Jan 21
Smith DironEVP, Chief Financial OfficerJan 19 '26Option Exercise0.001,709010,766Jan 21
Stephens JimPresident, CRM & NeuroJan 19 '26Option Exercise0.0075802,032Jan 21
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.